Ligand Pharmaceuticals Incorporated (LGND)vsNovartis AG ADR (NVS)
LGND
Ligand Pharmaceuticals Incorporated
$307.02
-4.87%
HEALTHCARE · Cap: $6.33B
NVS
Novartis AG ADR
$161.52
-1.40%
HEALTHCARE · Cap: $303.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 19644% more annual revenue ($57.36B vs $290.54M). LGND leads profitability with a 67.9% profit margin vs 17.5%. LGND appears more attractively valued with a PEG of 1.53. LGND earns a higher WallStSmart Score of 67/100 (B-).
LGND
Strong Buy67
out of 100
Grade: B-
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-6.3%
Fair Value
$174.97
Current Price
$307.02
$132.05 premium
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.52
$65.96 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 68 of every $100 in revenue as profit
Revenue surging 33.7% year-over-year
Earnings expanding 825.0% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LGND
The strongest argument for LGND centers on Profit Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 67.9% and operating margin at 13.5%. Revenue growth of 33.7% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bear Case : LGND
The primary concerns for LGND are PEG Ratio, P/E Ratio, Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
LGND profiles as a growth stock while NVS is a value play — different risk/reward profiles.
LGND carries more volatility with a beta of 1.01 — expect wider price swings.
LGND is growing revenue faster at 33.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
LGND scores higher overall (67/100 vs 48/100), backed by strong 67.9% margins and 33.7% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ligand Pharmaceuticals Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs globally. The company is headquartered in San Diego, California.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?